Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177059 · ClinicalTrials.gov registry record · Phase 2
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
A Phase 2 study of HIV-1, sponsored by Janssen-Cilag Pty.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 6
- Study locations
NCT01177059 is a Phase 2 study of HIV-1 that has completed, run by Janssen-Cilag Pty. The registered enrollment target is 68 participants, below the 129-participant average among 9 other HIV-1 trials with a reported enrollment target (47% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT01177059, a Phase 2 study of HIV-1, has completed, sponsored by Janssen-Cilag Pty.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this Observational Study is long term follow-up of the Human Immunodeficiency Virus -1 (HIV-1) infected patients who have received a gene therapy product (anti-HIV-1 Ribozyme \[OZ1\]) as part of an earlier phase 2 trial. Patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion. The study will monitor for and record any ill effects from the gene therapy product to provide long term safety information.
Conditions Studied
Interventions
- GENETIC OZ1 transduced cells
Study Locations (6)
Other
- - Darlinghurst
- - Surry Hills
- - Sydney
California
- - Los Angeles
- - San Francisco
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2004-12-06 |
| Est. Completion | 2017-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01177059
The ClinicalTrials.gov registry entry for NCT01177059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 9 other HIV-1 trials with a reported enrollment target (47% lower). The listed sponsor is Janssen-Cilag Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1 appearing as the primary indexed condition, and to 1 intervention - of which OZ1 transduced cells is the first listed.
NCT01177059 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT01177059 about?
NCT01177059 is a clinical study titled "Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial". The purpose of this Observational Study is long term follow-up of the Human Immunodeficiency Virus -1 (HIV-1) infected patients who have received a gene therapy product (anti-HIV-1 Ribozyme \[OZ1\]) as part of an earlier phase 2 trial. Patients are seen twice yearly until 5 years from initial infusi...
What is the current status of trial NCT01177059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2004-12-06. Estimated completion is 2017-11-30.
What conditions does trial NCT01177059 study?
This clinical trial studies the following conditions: HIV-1.
What interventions are being tested in trial NCT01177059?
The interventions under investigation include: OZ1 transduced cells (GENETIC).
Who is sponsoring clinical trial NCT01177059?
This trial is sponsored by Janssen-Cilag Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01177059 being conducted?
This trial has 6 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
RECRUITING · Phase 1
-
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
RECRUITING · Early Phase 1
-
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
ACTIVE NOT RECRUITING · Phase 1
-
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
ACTIVE NOT RECRUITING · Phase 3
-
Treatment De-Intensification and Residual HIV-1 in Youth
COMPLETED
-
Phase 1 Safety Study of Two Experimental HIV Vaccines
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.